{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.783","value":"3.47"},{"groupId":"OG001","spread":"24.180","value":"-5.43"}]}],"title":"Global Health Status/QoL, Change from BL; Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.675","value":"14.17"},{"groupId":"OG001","spread":"20.640","value":"17.97"}]}],"title":"Physical functioning, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.127","value":"8.33"},{"groupId":"OG001","spread":"35.441","value":"6.52"}]}],"title":"Role functioning, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.837","value":"11.34"},{"groupId":"OG001","spread":"15.977","value":"2.54"}]}],"title":"Emotional functioning, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.877","value":"2.78"},{"groupId":"OG001","spread":"14.058","value":"-7.25"}]}],"title":"Cognitive functioning, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.921","value":"9.03"},{"groupId":"OG001","spread":"29.914","value":"-11.59"}]}],"title":"Social functioning, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.307","value":"-10.88"},{"groupId":"OG001","spread":"30.473","value":"-6.76"}]}],"title":"Fatigue, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.228","value":"-4.86"},{"groupId":"OG001","spread":"19.603","value":"-4.35"}]}],"title":"Nausea/Vomiting, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.628","value":"-13.89"},{"groupId":"OG001","spread":"39.443","value":"-10.87"}]}],"title":"Pain, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.644","value":"-11.11"},{"groupId":"OG001","spread":"40.147","value":"-7.25"}]}],"title":"Dyspnea, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.104","value":"-16.67"},{"groupId":"OG001","spread":"35.441","value":"-10.14"}]}],"title":"Insomnia, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.822","value":"-18.06"},{"groupId":"OG001","spread":"24.529","value":"-7.25"}]}],"title":"Appetite Loss, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.215","value":"-13.89"},{"groupId":"OG001","spread":"41.013","value":"-5.80"}]}],"title":"Constipation, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.954","value":"-2.78"},{"groupId":"OG001","spread":"19.207","value":"5.80"}]}],"title":"Diarrhea, Change from BL at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.580","value":"4.17"},{"groupId":"OG001","spread":"30.942","value":"1.45"}]}],"title":"Financial Difficulties, Change from BL at Cycle 13"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a patient completed 30 item questionnaire that consists of 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The patient evaluates their health status over the previous week. There are 28 questions answered on a 4-point scale where1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7= Excellent (best). All of the scales and single-item measures are transformed to a score:0 to 100. For functioning scales and global QOL higher scores indicate better functioning (a positive change from Baseline indicates improvement); for symptom scales higher scores indicate more severe symptoms (a negative change from Baseline indicates improvement).","dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity \\[13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months\\] and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)"},{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity \\[13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months\\] and cyclophosphamide (CYC) 400 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.","id":"OG001","title":"Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)"}],"paramType":"MEAN","populationDescription":"Participants from the Safety Population, defined as all participants who received at least 1 dose of any study drug, with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Baseline (BL) (Day 1 of Cycle 1), Day 1 of Cycle 13 (Up to 1 year)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) During the Induction Phase in NDMM Participants","type":"SECONDARY","unitOfMeasure":"score on a scale"}